RonnieFLuyunMD

Oncology • Urbana, IL

Physician

Join to view full profile

Are you Dr. Luyun?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
611 W Park St
Oncologyhematology
Urbana, IL 61801
Phone+1 217-383-6636

Fax+1 217-383-3466

Summary

Dr. Ronnie Luyun, MD is an oncologist in Urbana, Illinois. He is currently licensed to practice medicine in Illinois and New York. He is affiliated with Samaritan Hospital - Main Campus and St. Peter's Hospital.

Education & Training

NYU Grossman Long Island School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2002
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1996 - 1999
Northwestern University The Feinberg School of MedicineClass of 1996

Certifications & Licensure

NY State Medical License 1999 - 2026
IL State Medical License 1996 - 2017
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia Start of enrollment: 2011 Apr 27
Terminated
Phase 2
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

140 citations
A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).
Aminah Jatoi, Howard L. Ritter, Amylou C. Dueck, Phuong L. Nguyen, Daniel A. Nikcevich
Lung Cancer. 2010-05-01
408 citations
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Thomas E. Witzig, Susan Geyer, Irene M. Ghobrial, David J. Inwards, Rafael Fonseca
Journal of Clinical Oncology. 2005-08-10
37 citations
Brief report: A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG ...
Thanyanan Reungwetwattana, Julian R. Molina, Sumithra J. Mandrekar, Katie Allen-Ziegler, Kendrith M. Rowland
Journal of Thoracic Oncology. 2012-05-01